Buy or sell guide
Should I Buy AMGN Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Amgen Inc..
Updated 2026-07-06
Wall Street currently rates AMGN buy with a 12-month price target of $353 (-5.8% downside). The sections below cover the bull case, key risks, and latest earnings context for AMGN.
Wall Street
Buy38 analystsConsensus target
$353 target (-5.8%)Current price $374.15Analyst sentiment
No recent analyst posts capturedWaiting for fresh postsEarnings context
EPS beat 8.0%Reported Thu Apr 30Wall Street verdict
Should I Buy AMGN Stock? Here's What Analysts Think
38 analysts currently cover AMGN. Below is their consensus rating, price target range, and implied upside.
According to 38 analysts, Amgen Inc. (AMGN) is rated Buy with a consensus 12-month price target of $353 — representing 6% downside from today's price of $374. The bull case target is $427, the bear case is $185.
AMGNBuy
From 38 analyst ratings- Current price
- $374.15
- Consensus Target
- $353 (-5.8% downside)
- Forward P/E
- 16.7x
- Coverage
- 38 analyst ratings
High target$427
Low target$185
At $374.15, the consensus setup implies -5.8% versus the 12-month target.
- 22 of 38 analysts lean Buy or Strong Buy, while 13 stay on Hold and 3 lean bearish.
- AMGN trades at roughly 16.7x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $185 to $427, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for AMGN right now.
Analyst ratings update weekly. Get AMGN's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
1 of 1 analysts raised targetsMorgan Stanley $340
Jun 2026Live commentary on X
What Analysts Are Saying About Amgen Inc. Right Now
Real posts from high-reach stock analysts mentioning AMGN, shown exactly as written. Sorted by engagement — most discussed first.
No recent posts captured
No high-reach analysts have posted about AMGN in the last 7 days. Check back after the next earnings release or market-moving event.
Should you buy AMGN?
Is AMGN a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for AMGN before you decide whether to buy, hold, or sell.
Current setup
AMGN beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Q4 2025 PerformanceAmgen exceeded revenue and adjusted EPS expectations in Q4 2025, projecting stronger earnings and revenue for 2026.
- Positive 2026 GuidanceThe company has provided upbeat guidance for 2026, indicating continued growth.
- Robust Late-Stage PipelineAmgen's late-stage pipeline is expected to drive volume-led growth, particularly with positive Phase 3 data for TEPEZZA.
- Analyst Consensus RatingAnalysts have a consensus rating of 'Buy' with a median price target of $353.00, implying a potential upside of 4.4%.
- Long-Term Revenue ProjectionsSome analysts project revenue near $44.4 billion and earnings of about $13.2 billion by 2029, assuming risks are contained.
- Strong Portfolio and M&A CapacityAmgen's broad portfolio and capacity for mergers and acquisitions are seen as strengths to offset pricing pressures.
Wall Street rates AMGN buy, giving the bull case institutional backing from 38 analysts.
Watch Out For
What can break the setup quickly
- Upcoming Patent ExpirationsAmgen faces potential headwinds from upcoming patent expirations for key franchises, impacting future revenue.
- Limited Pipeline VisibilityConcerns about limited pipeline visibility may necessitate continued business development for sustained growth.
- Intensifying Drug Pricing PressuresThere are growing concerns about global drug pricing efforts that could impact profitability.
- Stock Valuation ConcernsSome analysts suggest the stock may be overvalued, trading at a higher multiple than historical ranges.
- Fair Value EstimatesA more cautious view suggests a fair value around $243.49 per share, factoring in pricing reforms and cost inflation.
- Biosimilar Competition RisksBiosimilar competition and patent expiries are cited as risks that could limit revenue growth.
Watch whether new negative commentary on AMGN points to these structural risks or is simply reacting to short-term price moves.
AMGN Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $5.15 vs $4.77 est.Beat 8.0%
- Revenue
- $8.6B vs $8.6B est.Beat 0.5%
Consensus-Based Analysis Tools
Should I Buy AMGN?
Wall Street verdict, signals, and target summaries.
See Verdict
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
AMGN — Frequently Asked Questions
Quick answers to the most common questions about buying AMGN stock.
Should I buy AMGN stock right now?
Verdict
AMGN faces headwinds — analysts' $353 target is -5.8% from $374.15, suggesting limited near-term upside. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy AMGN?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with -5.8% upside to the $353 target. In the past 30 days, 1 of 1 covering analysts raised their price targets — a bullish signal.
What is the price target for AMGN stock?
Price Target
AMGN's consensus 12-month price target is $353, set by 38 Wall Street analysts. The bull case high is $427 and the bear case low is $185. From the current price of $374.15, this implies -5.8% upside.
Is AMGN overvalued or undervalued?
Valuation
AMGN appears overvalued — the $353 consensus target is -5.8% from today's $374.15. It trades at a forward P/E of 16.7x. Targets range from $185 (bear) to $427 (bull), reflecting different assumptions about growth and margins.
Should I buy AMGN before earnings?
Earnings
AMGN reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $353 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about AMGN stock?
Coverage
Of 38 analysts covering Amgen Inc. (AMGN): 0 Strong Buy, 22 Buy, 13 Hold, 3 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $353 (range $185–$427). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying AMGN stock?
Risks
3 of the 38 analysts covering AMGN rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Amgen Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.